Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GnRH agonists and uterine leiomyomas

F J Broekmans1

  • 1Department of Obstetrics and Gynecology, Academic Hospital of the University of Utrecht, The Netherlands.

Human Reproduction (Oxford, England)
|November 1, 1996
PubMed
Summary

Gonadotrophin-releasing hormone (GnRH) agonists effectively treat symptomatic uterine fibroids, but long-term use is limited by side effects. Combination therapy and specific surgical protocols offer improved outcomes for select patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of lifestyle intervention in subgroups of obese infertile women: a subgroup analysis of a RCT.

Human reproduction (Oxford, England)·2016
Same author

Effectiveness of lifestyle intervention in subgroups of obese infertile women: a subgroup analysis of a RCT.

Human reproduction (Oxford, England)·2016
Same author

Age-specific anti-Müllerian hormone and electrocardiographic silent coronary artery disease.

Climacteric : the journal of the International Menopause Society·2016
Same author

Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation?

Human reproduction (Oxford, England)·2015
Same author

The sub-optimal response to controlled ovarian stimulation: manageable or inevitable?

Human reproduction (Oxford, England)·2015
Same author

Testing for Ovarian Reserve in Assisted Reproduction programs: the current point of view.

Facts, views & vision in ObGyn·2014

Area of Science:

  • Gynecology
  • Reproductive Endocrinology

Background:

  • Gonadotrophin-releasing hormone (GnRH) agonists are established treatments for symptomatic uterine fibroids (leiomyomas).
  • Recent research focuses on optimizing GnRH agonist use and mitigating side effects.
  • Long-term monotherapy is restricted due to adverse health risks.

Purpose of the Study:

  • To review the established effectiveness and evolving role of GnRH agonists in managing uterine fibroids.
  • To evaluate different therapeutic schedules, including add-back and draw-back therapies.
  • To define the appropriate use of GnRH agonists in surgical settings.

Main Methods:

  • Review of existing literature on GnRH agonist efficacy and safety in leiomyoma treatment.
  • Analysis of different therapeutic regimens: monotherapy, add-back, draw-back, and sequential schedules.
  • Evaluation of pre-operative GnRH agonist use in relation to uterine volume and surgical approach.

Main Results:

  • Add-back therapy with steroids can reduce monotherapy disadvantages but is costly and best for uterus preservation.
  • Low-dose ('draw back') therapy lacks proven clinical efficacy.
  • Sequential GnRH agonist and steroid use may negate volume and symptom reduction benefits.
  • Pre-myomectomy GnRH agonist use is recommended for uteri > 600 ml and myoma-related anemia.
  • Pre-endoscopic surgery use has assumed benefits lacking definitive proof.

Conclusions:

  • GnRH agonists are effective for symptomatic fibroids, with add-back therapy offering a compromise for uterus preservation.
  • Careful patient selection and specific protocols are crucial for optimizing GnRH agonist therapy, particularly in surgical contexts.
  • Further evidence is needed to confirm benefits in certain pre-surgical applications.

Related Experiment Videos